Articles tagged "Liver transplantation"

2020 American Transplant Congress
The Liver Outcome Monitoring Registry Consortium: Data and Preliminary Outcome Results
J. Case¹, S. Kurian¹, B. Barrick¹, A. Robinson², M. Prentice², C. Marsh¹
¹Scripps Center for Organ and Cell Transplantation, La Jolla, CA, ²United Network for Organ Sharing Research Department, Richmond, VA
*Purpose: The Liver Outcome Monitoring Registry (LOMR) is an online platform for collecting and monitoring liver outcome data of marginal and DCD organs to be…
2020 American Transplant Congress
Management of Pancreatic Cancer after Liver Transplantation: A 27-Year Single-Center Experience
I. A. Ziogas, M. A. Rauf, L. K. Matsuoka, M. I. Montenovo, M. Izzy, S. P. Alexopoulos
Vanderbilt University Medical Center, Nashville, TN
*Purpose: The occurrence of de novo cancer after liver transplant (LT) is a leading cause of post-LT mortality and can be partially attributed to the…
2020 American Transplant Congress
Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates
A. Kardashian¹, J. Ge¹, C. McCulloch¹, M. R. Kappus², M. A. Dunn³, A. Duarte-Rojo³, M. L. Volk⁴, R. S. Rahimi⁵, E. C. Verna⁶, D. R. Ganger⁷, D. Ladner⁷, J. L. Dodge¹, B. Boyarsky⁸, M. McAdams-DeMarco⁸, D. L. Segev⁸, J. C. Lai¹
¹UCSF, SF, CA, ²Duke, Durham, NC, ³UPMC, Pittsburgh, PA, ⁴LLU, Loma Linda, CA, ⁵BSWH, Dallas, TX, ⁶Columbia, NY, NY, ⁷Northwestern, Chicago, IL, ⁸JHMI, Baltimore, MD
*Purpose: Frailty is associated with mortality in liver transplant (LT) waitlist candidates. We developed the Liver Frailty Index (LFI) to assess frailty in patients with…
2019 American Transplant Congress
Results of Litmus (nct 02541916): The Liver Immune Tolerance Bio Marker Utilization Study
A. Chruscinski¹, V. Rojas-Luengas¹, S. Moshkelgosha¹, J. Luo², H. Yowanto², Z. Galvin¹, L. Lilly¹, R. Smith¹, E. Renner¹, J. Zhang¹, D. Grant¹, O. Adeyi¹, H. Atkins³, P. Juni⁴, N. Selzner¹, S. Juvet¹, G. Levy¹
¹Multi-Organ Transplantation, University Health Network, Toronto, ON, Canada, ²Sciex, Brea, CA, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
*Purpose: Previously we reported a novel biomarker gene set for the identification of tolerance in murine models of rapamycin-induced cardiac tolerance and spontaneous hepatic tolerance.…
2019 American Transplant Congress
Alcohol Recidivism In Liver Transplant Recipients With Alcoholic Liver Disease: Does Six-months Abstinence Rule Still Holds True?
S. K. Satapathy¹, C. Thornburgh¹, J. Yu², J. Eason¹, S. Kedia², D. Maluf¹
¹UTHSC, Memphis, TN, ²University of Memphis, Memphis, TN
*Purpose: Liver transplant for alcoholic liver disease (ALD) continues to be a challenge for transplant centers, particularly related to the ethical dilemma of transplanting or…
2019 American Transplant Congress
Global and Domain Specific Cognition in Liver Transplant Recipients
D. Ko¹, L. Bratzke²
¹School of Nursing, Vanderbilt University, Nashville, TN, ²School of Nursing, University of Wisconsin-Madison, Madison, WI
*Purpose: Liver transplant (LT) recipients may experience global or domain-specific cognitive impairment (CI) (e.g., attention and memory) post-transplant due to multiple potential factors such as…
2019 American Transplant Congress
Hephaistos Study Outcome on Renal Function after 12 Month Everolimus Plus Reduced Tacrolimus in De Novo Liver Transplant Recipients versus Standard Tacrolimus
F. Braun¹, P. Schemmer¹, H. Schlitt¹, A. Pascher¹, C. Klein¹, U. Neumann¹, I. Kroeger², P. Wimmer², B. Nashan¹
¹Study Group, Hephaistos, Germany, ²Novartis Pharma GmbH, Nuernberg, Germany
*Purpose: The HEPHAISTOS study was designed to compare efficacy and safety of earlyuse of everolimus [EVR] combined with reduced tacrolimus [rTAC] versus Standard tacrolimus [TAC-C)…
2019 American Transplant Congress
Post-Reperfusion Hepatic Beta-Catenin Activation Regulates Graft Damage, Inflammatory Responses and Transplant Outcomes
H. Hirao, K. Kadono, S. Kageyama, K. Nakamura, T. Ito, J. Aziz, K. J. Dery, F. M. Kaldas, R. W. Busuttil, J. W. Kupiec‐Weglinski
Dumont-UCLA Transplant Center, UCLA, Los Angeles, CA
*Purpose: Hepatic ischemia-reperfusion injury (IRI), an innate-immune driven hepatic inflammation response, represents a major risk factor of early allograft dysfunction (EAD) and rejection in liver…
2019 American Transplant Congress
Does Secondary Simultaneous Liver Kidney versus Liver Alone Make a Difference in Terms of Patient and Graft Survival
C. Blanton, J. Reyes, M. Eerhart, P. Chlebeck, L. Fernandez
University of Wisconsin, Madison, WI
*Purpose: Survival benefits have been shown with primary simultaneous liver kidney (SLK) transplantation as well as kidney after primary liver transplant when patients develop kidney…
2019 American Transplant Congress
Comparison of Two Dosing Regimens of Valganciclovir for Cytomegalovirus Prophylaxis in High-Risk Liver Transplant Recipients
A. L. Bixby, L. Fitzgerald, L. Cotiguala, J. M. Park, D. Kaul, C. Sonnenday, S. Tischer
Michigan Medicine, Ann Arbor, MI
*Purpose: Significant controversy surrounds the optimal dose and duration of valganciclovir (VGCV) to prevent CMV in high-risk (D+/R-) liver transplant (LT) recipients. High doses cause…